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Apolipoproteins and Diabetic
Retinopathy
I
nt h i si s s u eo fDiabetes Care Sasongko
et al. (1) make the intriguing observa-
tion that apolipoprotein (apo)B and
apoA-I, and particularly the apoB-to-
apoA-I ratio, are related to the presence
of diabetic retinopathy in a small cohort
of type 1 and type 2 diabetic patients.
Moreover, this ratio correlated with the
retinopathy severity and also was a better
predictor of retinopathy than traditional
lipid measures such as total cholesterol,
LDLorHDLcholesterol,oreventheLDL-
to-HDL cholesterol ratio.
This study raises many important
questions. For example, why are these
relationships between retinopathy and
lipoproteins seen in this small study,
whereas previous studies, some in much
larger cohorts, have not shown a consis-
tent relationship? Did measurement of
apolipoproteins rather than the lipid
components of the lipoproteins make
the difference? Lipids and lipoproteins are
well-accepted risk factors for macrovascu-
lardiseaseindiabetesviamechanismsthat
arereasonablywellunderstood.However,
do lipids and lipoproteins play a role in
microvascular complications such as ret-
inopathy in addition to better known risk
factorssuchasdiabetesduration,glycemic
control, and hypertension? And if so, by
what mechanisms does HDL protect and
the apoB-containing lipoproteins increase
the risk of retinopathy?
In the current study, stronger rela-
tionshipswereobservedbetweenretinop-
athy and apolipoproteins than with lipid
components of the lipoproteins. ApoA-I
is the major structural apolipoprotein
present in HDL and is reﬂective of the
number of HDL particles. A single mole-
culeofapoBispresentinLDL,aswellasin
VLDL, remnant lipoproteins (often pres-
ent in the intermediate-density lipopro-
tein [IDL] density range) and lipoprotein
(a) (Lp(a)), another atherogenic lipopro-
tein. Because each of these lipoproteins
contains a single molecule of apoB, apoB
concentration is a measure of the total
number of these atherogenic particles. If
these lipoproteins also have an adverse
effect on microvascular complications
such as retinopathy, apoB levels might
be expected to show a better relationship
with retinopathy than individual measure-
ments of LDL, VLDL, IDL, or Lp(a) lipids.
Similarly, if HDL has protective proper-
ties in the eye as well as in the artery wall,
apoA-I levels might be expected to be a
better predictor of risk than HDL lipids,
sinceHDLparticlesareveryheterogeneous
in composition.
The relationship between lipids and
lipoproteins with atherosclerotic cardio-
vascular disease (CVD) might provide
important clues to the relationship be-
tween lipoproteins and retinopathy. The
earliest observed relationships were be-
tween plasmacholesterolandCVD(2–4).
Later LDL cholesterol itself was found to
be a strong predictor of CVD risk (5,6).
Basic studies suggested many potential
mechanisms by which LDL might be ath-
erogenic, including the ability to be taken
up and be retained in the artery wall, after
which they can undergo various forms of
modiﬁcation, including oxidative modiﬁ-
cation and hydrolysis of components of
the lipoprotein by enzymes such as secre-
tory phospholipases and sphinogomye-
linase (7–13). Components of modiﬁed
lipoproteins can damage arterial cells or
be atherogenic by other mechanisms.
However, the importance of LDL as a
risk factor was only ﬁrmly established
by randomized controlled clinical trials
(RCTs) that demonstrated that LDL low-
ering reduced the risk of CVD (14–16).
The role of HDL as an atheroprotective
lipoprotein emerged at about the same
time. Several mechanisms by which
HDL might be atheroprotective (17,18)
include its ability to promote reverse
cholesterol transport, as well as its anti-
inﬂammatory, antioxidant, and anti-
thrombotic properties (19). However,
RCTs have yet to clearly demonstrate a
role for HDL in preventing CVD events.
Although there is a clear association be-
tween triglycerides, which are trans-
ported in plasma as VLDL, and CVD
(20),RCTshaveyettoprovidedeﬁnitive
evidence for their causal role in CVD.
Because of this type of evidence, guide-
lineshavegenerallyfocusedonLDLlow-
ering, although more recent guidelines
have paid increasing attention to HDL
and triglycerides (21).
The role of apolipoproteins in CVD
risk is now receiving increasing attention.
Correlations of apoB and apoA-I, as well
as the ratio of apoB to apoA-I, with CVD
risk are well described. Whether apolipo-
proteins are better CVD risk predictors
thantraditionallipidmeasurementsremains
controversial. In the Apolipoprotein-
related Mortality Risk (AMORIS) trial,
both apolipoproteins and traditional lipid
measurements were predictive, but the
apolipoproteins were slightly more sig-
niﬁcant, particularly in patients with
lower LDLlevels(22).The INTERHEART
study showed that the apoB-to-apoA-I ra-
tio was superior to any traditional choles-
terol ratio in estimation of risk for acute
myocardial infarction (23). Other studies
have not shown apolipoproteins to be
better predictors of CVD risk than tradi-
tional lipid measurements. For example,
the apoB-to-apoA-I ratio was comparable
with traditional lipid ratios in predicting
CVD risk and did not improve upon the
total cholesterol-to-HDL ratio in the Fra-
mingham cohort (24). Moreover, case
control analysis of healthy participants
from the European Prospective Investiga-
tion of Cancer (EPIC)-Norfolk study
showed that apoB-to-apoA-I ratio was in-
dependently associated with CVD risk
but did not add to existing measures of
lipid analysis (25). Thus, although both
traditional lipids and lipoproteins and
apolipoprotein ratios are good CVD risk
predictors, it remains to be seen whether
apolipoprotein measurements will re-
place traditional risk factors in future
CVD guidelines.
What about diabetes, lipoproteins,
and CVD risk? Similar relationships ap-
pear to exist between lipoproteins and
CVD risk as for individuals without di-
abetes. In the UK Prospective Diabetes
Study (UKPDS), LDL cholesterol was the
strongest predictor of risk (26). Other
studies have shown that triglycerides
and low HDL also are important risk pre-
dictorsindiabetes(27).Inthe few studies
in which apolipoproteins have been as-
sessed in patients with diabetes, apoB-
to-apoA-I ratio predicts CVD risk similar
to that seen in nondiabetic cohorts. In the
CollaborativeAtorvastatinDiabetesStudy
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type 2 diabetic patients, the apoB-to-
apoA-I ratio improved upon the non-
HDL-to-HDL ratio for predicting CVD,
but it was only a marginal improvement
upon the LDL-to-HDL ratio (28). In the
Fenoﬁbrate Intervention and Event Low-
ering in Diabetes (FIELD) study of feno-
ﬁbrate treatment in type 2 diabetic
patients, in contrast with some studies
in nondiabetic populations, traditional
lipid ratios were as strong as the apoB-
to-apoA-I ratio in predicting CVD risk
(29). Future studies should help deter-
mine whether the apoB-to-apoA-I ratio
is more predictive of CVD in nondiabetic
versus diabetic subjects.
The mechanisms by which dyslipide-
miamightincreaseCVDriskarerelatively
well understood. However, it is still un-
clear whether lipoproteins play a role in
the pathogenesis of diabetic retinopathy,
and if so, how they are involved. Dyslip-
idemia has been associated with an in-
creased risk of diabetic retinopathy in
observational studies (30,31). In the Di-
abetes Control and Complications Trial
(DCCT), the severity of retinopathy was
associated with increasing triglyceride
levels and inversely correlated with HDL
levels (32). Treatment with fenoﬁbrate, a
drug that primarily reduces triglycerides
and modestly increases HDL cholesterol
levels, reduced the need for laser treat-
ment of vision-threatening diabetic reti-
nopathy in FIELD (33). However, this
ﬁnding was not attributable to changes in
lipid levels, which suggests that fenoﬁbrate
had pleiotropic effects above and beyond
lipid modiﬁc a t i o n .M o r er e c e n t l y ,ad e -
crease in the rate of progression of diabetic
retinopathy with fenoﬁbrate treatment was
alsoobservedintheActiontoControlCar-
diovascular Risk in Diabetes (ACCORD)
trial (34). Despite these clues, potential
mechanisms by which lipoproteins might
affect diabetic retinopathy remain unclear.
In the present study, low HDL (or apoA-I)
levelspredictedretinopathyriskmorethan
highLDL(orapoB)levels.Itisconceivable
that some of the properties of HDL that
areatheroprotectivemightalsoplayarole
in preventing retinopathy. Mechanisms
by which apoB-containing lipoproteins
might exacerbate retinopathy are less
clear. They nonetheless open the door
for more mechanistic studies to better
understand the pathogenesis of diabetic
retinopathy.
So should we use apoB-to-apoA-I
ratio to predict retinopathy risk? The
sample size in this study was small and
its provocative ﬁndings need to be repli-
cated in larger studies. Moreover, it also
will be important to conﬁrm the potential
predictive role of apolipoproteins and
lipoproteins in longitudinal studies.
Even if relationships between dyslipide-
mia and retinopathy are conﬁrmed, the
criticalquestioniswhethertherapyaimed
at altering lipids and lipoproteins will
prevent the onset or progression of di-
abetic retinopathy. Preliminary studies
with ﬁbrates are encouraging but may
be because of effects of this class of drug
distinct from their effect on lipids and
lipoproteins. Studies with other drugs
that lower apoB-containing lipoproteins
and raise HDL need to be performed.
Effective therapies are available to lower
LDLandapoB.Lesseffectivestrategiesare
currently available to raise HDL and
apoA-I levels, although this is an intense
area of focus for the pharmaceutical in-
dustry. More studies need to show that
the relationship between retinopathy and
l i p o p r o t e i n si ss u f ﬁciently robust to
warrant a RCT of lipid-altering therapy.
And the relative importance of lipid
therapy versus the more traditional ap-
proaches of tight glycemic and blood
pressure control needs to be evaluated.
However, the possibility that lipid and
lipoprotein modiﬁcation might, with
time, supplement these other strategies
provides light at the end of the tunnel for
further reducing this devastating compli-
cation of diabetes.
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